Ted Haack is vice president at LatticePoint Consulting and serves as a senior advisor to public and private life-sciences companies based on his 30 years of experience in market access, commercialization, and financial reporting. His expertise includes business development and licensing, portfolio planning, international expansion, risk assessment, royalty stream valuation, and governance. Haack also has significant experience in intellectual property, including loss of exclusivity strategy in both the generics and biosimilar spaces.

Haack spent 17 years in international finance, pricing, and market access in the biopharma industry at Pfizer, Genzyme, and Schering-Plough in the US and Germany. Haack spent six months based in Kigali, Rwanda, as a Pfizer global health fellow, working with rural health centers on process improvement. Before entering the biopharma industry, he was an audit manager at Deloitte in the Parsippany, New Jersey, and Frankfurt, Germany, offices, where he audited a variety of public companies and their international affiliates including Securities and Exchange Commission reporting, mergers-and-acquisitions due diligence, and financial integration. He qualifies as an audit committee financial expert.

Haack currently serves as an independent director on the board of Promethera Biosciences SA (a private clinical-stage cell-therapy company in Belgium). He is an active member of the NACD and holds their Directorship Certification and the Community Emergency Response Team (CERT) certificate in cyber-risk oversight. Haack holds a bachelor of science in accountancy from Villanova University, a master of business administration from New York University, and a master of arts in international affairs from the Fletcher School at Tufts University. He is professionally fluent in German.